EDIT – editas medicine, inc. (US:NASDAQ)
Stock Stats
News
Editas Medicine Outlines 2025 Strategic Priorities and Milestones [Yahoo! Finance]
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Form SCHEDULE 13G/A Editas Medicine, Inc. Filed by: Deep Track Capital, LP
Form 8-K Editas Medicine, Inc. For: Jan 13
Form 8-K Editas Medicine, Inc. For: Dec 16
Form 8-K Editas Medicine, Inc. For: Dec 11
Form 8-K Editas Medicine, Inc. For: Dec 06
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.